Clinic Roundup

Genfit SA, of Lille, France, reported partial results from a pharmaco-clinical study demonstrating a hepatic mechanism of action for GFT505 in insulin-resistant patients. Results for 19 of 22 patients showed that the drug significantly increased the response of the liver to insulin action.